---
title: "Eli Lilly and Company (LLY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LLY.US.md"
symbol: "LLY.US"
name: "Eli Lilly and Company"
industry: "Pharmaceuticals"
datetime: "2026-05-19T20:30:08.659Z"
locales:
  - [en](https://longbridge.com/en/quote/LLY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LLY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LLY.US.md)
---

# Eli Lilly and Company (LLY.US)

## Company Overview

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.lilly.com](https://www.lilly.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: B (0.31)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 47.43% |  |
| Net Profit YoY | 127.60% |  |
| P/B Ratio | 29.92 |  |
| Dividend Ratio | 0.65% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 933566088127.29 |  |
| Revenue | 72249000000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 107.65% | A |
| Profit Margin | 34.99% | A |
| Gross Margin | 81.93% | A |
| Revenue YoY | 47.43% | A |
| Net Profit YoY | 127.60% | A |
| Total Assets YoY | 30.41% | A |
| Net Assets YoY | 96.87% | A |
| Cash Flow Margin | 81.02% | C |
| OCF YoY | 47.43% | A |
| Turnover | 0.70 | B |
| Gearing Ratio | 73.24% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Eli Lilly and Company",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "47.43%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "127.60%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "29.92",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.65%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "933566088127.29",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "72249000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "107.65%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "34.99%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "81.93%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "47.43%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "127.60%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "30.41%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "96.87%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "81.02%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "47.43%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.70",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "73.24%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 36.93 | 50/190 | 58.60 | 51.04 | 43.75 |
| PB | 29.92 | 187/190 | 42.93 | 39.97 | 34.29 |
| PS (TTM) | 12.92 | 121/190 | 15.82 | 14.10 | 12.91 |
| Dividend Yield | 0.65% | 29/190 | 0.74% | 0.68% | 0.58% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **33**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 18 | 55% |
| Overweight | 6 | 18% |
| Hold | 6 | 18% |
| Sell | 1 | 3% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1014.88 |
| Highest Target | 1500.00 |
| Lowest Target | 850.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LLY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LLY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LLY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LLY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**